<SEC-DOCUMENT>0000929638-25-003514.txt : 20250918
<SEC-HEADER>0000929638-25-003514.hdr.sgml : 20250918
<ACCEPTANCE-DATETIME>20250918174712
ACCESSION NUMBER:		0000929638-25-003514
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250918
DATE AS OF CHANGE:		20250918

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silexion Therapeutics Corp
		CENTRAL INDEX KEY:			0002022416
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94600
		FILM NUMBER:		251324487

	BUSINESS ADDRESS:	
		STREET 1:		12 ABBA HILLEL ROAD
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5250606
		BUSINESS PHONE:		972-8-6286005

	MAIL ADDRESS:	
		STREET 1:		12 ABBA HILLEL ROAD
		CITY:			RAMAT GAN
		STATE:			L3
		ZIP:			5250606

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Biomotion Sciences
		DATE OF NAME CHANGE:	20240506

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lind Global Fund III LP
		CENTRAL INDEX KEY:			0002071860
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		444 MADISON AVENUE
		STREET 2:		41ST FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		646-701-7428

	MAIL ADDRESS:	
		STREET 1:		444 MADISON AVENUE
		STREET 2:		41ST FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0002071860</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<securitiesClassTitle>Ordinary shares, par value $0.0135 per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>09/12/2025</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0002022416</issuerCik>
<issuerName>Silexion Therapeutics Corp</issuerName>
<issuerCusip>G1281K122</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>12 Abba Hillel Road</com:street1>
<com:city>Ramat-Gan</com:city>
<com:stateOrCountry>L3</com:stateOrCountry>
<com:zipCode>5250606</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Lind Global Fund III LP</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>224050</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>224050</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>224050</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>9.9</classPercent>
<typeOfReportingPerson>PN</typeOfReportingPerson>
<comments>(1) The reporting person's ownership consists of (i) 106,250 ordinary shares, (ii) 106,250 warrants to purchase ordinary shares (the "Series A-1 Warrants") and (iii) 106,250 warrants to purchase ordinary shares (the "Series A-2 Warrants, together with the Series A-1 Warrants, the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 224,050 shares in the aggregate.&#13;
(2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 9.99% of the Company.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Lind Global Partners III LLC</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>DE</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>224050</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>224050</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>224050</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>9.9</classPercent>
<typeOfReportingPerson>PN</typeOfReportingPerson>
<comments>(1) The reporting person's ownership consists of (i) 106,250 ordinary shares, (ii) 106,250 Series A-1 Warrants and (iii) 106,250 Series A-2 Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 224,050 shares in the aggregate.&#13;
(2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 9.99% of the Company.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>EASTON JEFF</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>224050</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>224050</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>224050</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>9.9</classPercent>
<typeOfReportingPerson>IN</typeOfReportingPerson>
<comments>(1) The reporting person's ownership consists of (i) 106,250 ordinary shares, (ii) 106,250 Series A-1 Warrants and (iii) 106,250 Series A-2 Warrants; however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 224,050 shares in the aggregate.&#13;
(2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 9.99% of the Company.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Silexion Therapeutics Corp</issuerName>
<issuerPrincipalExecutiveOfficeAddress>12 Abba Hillel Road, Ramat-Gan, Israel, 5250606</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"):&#13;
&#13;
Lind Global Fund III LP, a Delaware limited partnership;&#13;
Lind Global Partners III LLC, a Delaware limited liability company; and&#13;
Jeff Easton, an individual and a citizen of the United States of America.&#13;
&#13;
Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.&#13;
&#13;
Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>The address of the principal business office for each of the Reporting Persons is:&#13;
&#13;
444 Madison Ave, Floor 41 &#13;
New York, NY 10022</principalBusinessOfficeOrResidenceAddress>
<citizenship>See Row 4 of cover page for each Reporting Person.</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>See Row 9 of cover page for each Reporting Person.</amountBeneficiallyOwned>
<classPercent>See Row 11 of cover page for each Reporting Person.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>See Row 5 of cover page for each Reporting Person.</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>See Row 6 of cover page for each Reporting Person.</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>See Row 7 of cover page for each Reporting Person.</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>See Row 8 of cover page for each Reporting Person.</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>Lind Global Fund III LP</reportingPersonName>
<signatureDetails>
<signature>By: Lind Global Partners III LLC, its General Partner, By:  /s/ Jeff Easton</signature>
<title>Jeff Easton, Managing Member</title>
<date>09/18/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Lind Global Partners III LLC</reportingPersonName>
<signatureDetails>
<signature>By: Lind Global Partners III LLC, its General Partner, By:  /s/ Jeff Easton</signature>
<title>Jeff Easton, Managing Member</title>
<date>09/18/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>EASTON JEFF</reportingPersonName>
<signatureDetails>
<signature>/s/ Jeff Easton</signature>
<title>Jeff Easton</title>
<date>09/18/2025</date>
</signatureDetails>
</signatureInformation>
</formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Morgan Lewis
         Document created using Broadridge PROfile 25.8.1.5328
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div><br>
  </div>
  <div>
    <div style="text-align: right; margin-bottom: 12pt; font-family: 'Times New Roman'; font-weight: bold;"> Exhibit 99.1<br>
    </div>
    <div style="text-align: center; margin-bottom: 12pt; font-family: 'Times New Roman'; font-weight: bold;">JOINT FILING AGREEMENT</div>
    <div style="text-align: justify; text-indent: 36pt; margin-bottom: 12pt; font-family: 'Times New Roman';">The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary shares, par value $0.0135 per share,
      of Silexion Therapeutics Corp shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.</div>
    <div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman';">September 18, 2025</div>
    <table style="border-collapse: collapse; width: 30%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z928112d8311b49c38df68d75c627d61b" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td colspan="3" style="width: 100%; vertical-align: top;">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">LIND GLOBAL FUND III LP</div>
          </td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: middle;">&#160;</td>
          <td colspan="2" style="width: 81.81%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="width: 1.69%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 80.11%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">Lind Global Partners III LLC</div>
          </td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: top;">&#160;</td>
          <td style="width: 1.69%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 80.11%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">its General Partner</div>
          </td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: middle;">&#160;</td>
          <td colspan="2" style="width: 81.81%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="width: 1.69%; vertical-align: bottom;">&#160;</td>
          <td style="width: 80.11%; vertical-align: top; border-bottom: 1px solid #000000;">
            <div>
              <div style="font-family: 'Times New Roman';">/s/ Jeff Easton</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">Name:</div>
          </td>
          <td style="width: 1.69%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 80.11%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">Jeff Easton</div>
          </td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 1.69%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 80.11%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">Managing Member</div>
          </td>
        </tr>
        <tr>
          <td colspan="3" style="width: 100%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="width: 100%; vertical-align: top;">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">LIND GLOBAL PARTNERS III LLC</div>
          </td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: middle;">&#160;</td>
          <td colspan="2" style="width: 81.81%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="width: 1.69%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 80.11%; vertical-align: top; border-bottom: 1px solid #000000;">
            <div>
              <div style="font-family: 'Times New Roman';">/s/ Jeff Easton</div>
            </div>
          </td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">Name:</div>
          </td>
          <td style="width: 1.69%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 80.11%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">Jeff Easton</div>
          </td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 1.69%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 80.11%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">Managing Member</div>
          </td>
        </tr>
        <tr>
          <td colspan="3" style="width: 100%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td colspan="3" style="width: 100%; vertical-align: middle;">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">JEFF EASTON</div>
          </td>
        </tr>
        <tr>
          <td colspan="3" style="width: 100%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 18.19%; vertical-align: top;">
            <div style="font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="width: 1.69%; vertical-align: bottom;">
            <div style="font-family: 'Times New Roman';">&#160;</div>
          </td>
          <td style="width: 80.11%; vertical-align: top; border-bottom: 1px solid #000000;">
            <div>
              <div style="font-family: 'Times New Roman';">/s/ Jeff Easton</div>
            </div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
